Specialists about our tests

There are tumor markers circulating in the blood. On the basis of liquid biopsy we can conclude with high probability that the patient has cancer. The sensitivity of the test depends on the type of malignancy. Cancer is very complicated. Note, however, that even a biopsy of the metastasis does not always allow to determine the primary focus.

Dr. Andrzej Cichocki, specialist in the field of oncology and surgical oncology, director of the Department of Surgical Oncology in the Center of Oncology – Maria Sklodowska-Curie Institute.

Drawing genetic material from the tumor is technically easier and we can obtain a greater amount of test material in this way. Liquid biopsy is a much more complex method. Analysis of genetic material is technically much more complicated. However, the results we receive on this basis, allow us to conclude ifa cancer develops in the body. This technique is also significantly less invasive to the patient.

Prof. Włodzimierz Baranowski, specialist in gynecology and oncological gynecology, longtime head of the Department of Gynecology and Oncological Gynecology in Military Medical Institute in Warsaw.

With great satisfaction we welcome on our market the Chronix Biomedical Prostate Cancer test, which is based on the use of chromosomal instability analysis of extracellular DNA in the serum of patients with prostate cancer. Unlike other genetic tests based on the search for specific mutations of single genes, this test is based on the identification of changes in the entire genome.

Prof. Andrzej Borkowski, Professor of Medical University of Warsaw, 2002 – 2015 Chairman of the Scientific Committee of the Polish Society of Urology.

Liquid biopsy is a tool that works out in the diagnosis of malignant tumors. Genetic material which we receive on the basis of this study is fully valuable. In case of breast cancer detection, the CNI sensitivity is higher than 90%.

Dr. Monika Nagadowska, Department of Breast Cancer in Oncology Center in Warsaw.

Delta Dot Test can be an effective tool for monitoring the progress of treatment. Immediate information about the efficacy of this therapy is very important. We can gain such knowledge on the basis of the CNIratio.

Dr. Monika Nagadowska, Department of Breast Cancer in Oncology Center in Warsaw.

Liquid biopsy and Delta Dot test arebest solutions to control the results of applied therapy. Theyshow how the treatment goes.

Prof. Janusz A. Siedlecki, head of the Department of Molecular and Translational Oncology in Warsaw.

Delta Dot is an effective monitoring of the treatment. Knowing the finallevel of the amount of residual DNA of cancer one can monitor the effectiveness of therapy. In some instances, liquid biopsy may overtake imaging, providing immediate information.

Dr. Andrzej Cichocki, specialist in the field of oncology and surgical oncology, director of the Department of Surgical Oncology in the Center of Oncology – Maria Sklodowska-Curie Institute.

Magnetic resonance imaging and computed tomography can onlybe as good as the diagnostician, who performs them. This is the problem of all imaging tests.

Prof. Piotr Radziszewski, urologist, Head of the Department of General, Oncologic and Functional Urology in Medical University of Warsaw.

Imaging is a leading direction to monitor the effectiveness of therapy. Delta Dot Test is an equally interesting study. The classic academic approach and the Delta Dot test should support each other. If, for example, imaging test shows no tumor change, and performed Delta Dot test finds that blood continues to circulate cancer cells, it means that the therapy did not remove the entire tumor.

Prof. Włodzimierz Baranowski, specialist in gynecology and oncological gynecology, longtime head of the Department of Gynecology and Oncological Gynecology in Military Medical Institute in Warsaw.